Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Autor: Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M Liberati, Hartmut Goldschmidt, Andrew Belch, Hila Magen, Alessandra Larocca, Jacob P Laubach, Maria T Petrucci, Donna Reece, Darrell White, María-Victoria Mateos, Ivan Špička, Mihaela Lazaroiu, Jesús Berdeja, Jonathan L Kaufman, Ying-Ming Jou, Alex Ganetsky, Mihaela Popa McKiver, Sagar Lonial, Katja Weisel, Irwindeep Sandhu, Monika Podhorecka, Antonio Palumbo, Adi Shacham-Abulafia, Iuliana Vaxman, Ofer Shpilberg, Britta Besemer, Maurizio Martelli, Roberto Foà, Paolo De Fabritiis, Tommaso Caravita di Toritto, Emanuil Gheorghita, Albert Oriol, Philip Rowlings, Angelucci Emanuele, Angelo M Carella, Massimo Offidani, Joan Bladé, Luis F Casado, Heather Oakervee, Victoria Panelli, Luis Meza, Thomas Kühr, Miguel Granell, Don Benson, Rajesh Nair, Viran Holden, James Reeves, Richard W Eek, Patricia A Walker, John Catalano, András Rosta, Ewa Lech-Marańda, Christy Samaras, Anthony Reiman, Robert Weaver, Peter Acs, Andrew Grigg, Bernard De Prijck, Martha Louzada, Leonard Minuk, Michael Sebag, Martine Klausmann, Manfred Welslau, Andrzej Hellmann, Catalin Danaila, Pamela Becker, William Bensinger, Bruce Porterfield, Manuel Modiano, Stephen M Schultz, Robert Manges, Huey-Shin Cindy Lee, James X Gray, Matthew P Wright, Marie-Christine Vekemans, Aryan Hamed, Zoltán Gasztonyi, Gábor Mikala, Tamás Masszi, Barbara Gamberi, Kazimierz Kuliczkowski, Lidia Usnarska-Zubkiewicz, Enrique Bengoechea, María AE Gutiérrez, Miguel TH García, Jesús San-Miguel, Christoph Driessen, Rajesh Behl, Warren Brenner, Carl Gray, Vincent Hansen, Mehdi Moezi, Hector V Cortes, Charles Yen, Laurent Gressot, Noemi Horvath, James M D'Rozario, Maya Latimer, Maria-Christine Kyrtsonis, Evgeni Chubar, Moshe Mittelman, Luca Baldini, Patrizia Tosi, Angelo Vacca, Wiesław W Jędrzejczak, Tadeusz Robak, Juan J Lahuerta, Jennifer Carney, Franklin Chen, Robert Hirsch, Marco Ruiz, Alvaro Alencar, Madan Jagasia, Samer Kasbari, Philip Kuriakose, Aftab Mahmood, Madhu Chaudhry, Gary Cohen, Stephen Noga, Sch Roa, Andrzej Jakubowiak, Cara Rosenbaum, Michel Delforge, Vanessa Delrieu, Chantal Doyen, Deeren Dries, Hilde Demuynck, Rik Schots, Vladimir Maisnar, Igor W Blau, Heinz A Dürk, Andrea Kerkhoff, Martin Kropff, Markus Munder, Christoph Röllig, Christof Scheid, Argiris S Symeonidis, Árpád Illés, Mark Coyne, Peter O'Gorman, Patrick Hayden, Michael O'Dwyer, Dina Ben-Yehuda, Andrei Braester, Anatoly Nemets, Gilles Lugassy, Yossi Cohen, Naomi Rahimi-Levene, Alberto Bosi, Sara Pezzatti, Fausto Rossini, Enrico M Pogliani, Antonello Pinto, Mieczysław Komarnicki, Gabriela Borsaru, Razvan Stoia, Boris Afanasyev, María A Goñi, Ana V Carboneras, Sarah Ali, S. Eric Rubenstein, Salvador Caputto, Thomas Cosgriff, Suzanne Fanning, Ali Khojasteh, Andrew Liman, Albert Malcolm, Nandagopal Vrindavanam, Ravindranath Patel, Rajesh Belani, Marie Shieh, Keith Stockerl-Goldstein, Charles Strnad, Robert Stuart, Saurabh Chhabra, Luciano Costa, Haresh Jhangiani, Bradley Augustson, Robin Filshie, Amanda Johnston, Mark S Hertzberg, Philippe Mineur, Susan Fox, Rami Kotb, Vi Dao, Richard LeBlanc, Evzen Gregora, Annamaria Brioli, Lars-Olof Mügge, Mathias Hänel, Christian Langer, Eleni Kapsali, Evangelos Briasoulis, Despoina Kyriakou, Izhar Hardan, Netanel A Horowitz, Cangialosi Clotilde, Francesco Fabbiano, Barbara Castagnari, Fabio Ciceri, Gerardo Musuraca, Andrzej Deptała, Janusz Kłoczko, Marius Balea, Ana-Maria Vladareanu, Victor Rossiev, Adrián Alegre, Cristina Encinas, Jorge Gayoso, Thomas Pabst, Neil Rabin, Sherri Arledge, Fernando Cabanillas, Joseph Catlett, Tarek Chidiac, David Clarkson, Madhav Dhodapkar, George Geils, Cyrus MA Khan, Entezam Sahovic, Mohamad Khasawneh, Rajesh Sehgal, Oscar Ballester, Moshe Levy, Joseph Fay, Kiem Liem, Matthew Lunning, Julie Vose, Edward Faber, Donald MacFarlane, Raymond Hohl, Tariq Mahmood, Birbal Bhaskar, Martha Mims, Ira Oliff, Agne Paner, John Maciejewski, Arvinda Padmanabhan, Robert Richard, Amit Sanyal, Gary Schiller, Harry Staszewski, Don Stevens, Christopher Vaughn, Kevin Windsor

Publikováno v: The Lancet Haematology. 9:e403-e414

BACKGROUND: Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408fd2626647bda321f302f4c5f4b247
https://doi.org/10.1016/s2352-3026(22)00103-x

Data from Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Autor: Johann S. de Bono, Li Yan, Timothy A. Yap, Brianne Kaiser, Victor Moreno, Kyriakos P. Papadopoulos, Ying-Ming Jou, Ernestina Tetteh, Anne Morosky, Keith A. Shannon, Maria Learoyd, Pearl Huang, Paul D. Smith, Eric H. Rubin, Jeffrey M. Skolnik, Christopher R. Garrett, David Olmos, Richard D. Baird, Amita Patnaik, David R. Gandara, Vassiliki Papadimitrakopoulou, Udai Banerji, Michael Ong, Khurum Khan, Anthony W. Tolcher

Purpose: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7c62bba7d8cb8fd656692135284d90
https://doi.org/10.1158/1078-0432.c.6524007

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Autor: Meletios A. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, David Yao, Prianka Das, Jesús San-Miguel

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132 ), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e288b2851c6e74f2ff97875cf62ed97
https://pubmed.ncbi.nlm.nih.gov/35960908

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Autor: Paul G. Richardson, Kenneth C. Anderson, Jesús F. San-Miguel, Andrew R. Belch, Andrew Spencer, Ka Lung Wu, Adam Walter-Croneck, Morio Matsumoto, Sagar Lonial, Katja Weisel, Sebastian Grosicki, Maria-Victoria Mateos, Hermann Einsele, Ivan Spicka, Darrell White, Meral Beksac, Ying-Ming Jou, Masafumi Taniwaki, Philippe Moreau, Donna E. Reece, Alex Ganetsky, Robert Z. Orlowski, Hila Magen, Anil K. Singhal, Ofer Shpilberg, Christoph Röllig, Meletios A. Dimopoulos, Heather Oakervee

Publikováno v: Blood Cancer Journal
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, Vol 10, Iss 9, Pp 1-10 (2020)

Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lena

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b898853c5ff7619272a8e462194b8f
https://doi.org/10.1038/s41408-020-00357-4

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

Autor: Suresh Shelat, Paul G. Richardson, Ellice Wong, Ying-Ming Jou, Cara A. Rosenbaum, Kenneth C. Anderson, Michael Robbins, Jacob P. Laubach, Mark Lynch, Keith Stockerl-Goldstein, Sundar Jagannath, Madhav V. Dhodapkar

Publikováno v: British Journal of Haematology

Summary Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody‐depe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bc3fc58f093ff82614612230c9e317
https://doi.org/10.1111/bjh.15384